Thank you, Rajiv. I will first provide commentary on our Q1 '24 results, followed by the guidance for Q2 '24 and fiscal year '24. Q1 '24 was a good quarter in which we exceeded the high end of the range on all guided metrics. ACV billings in Q1 was $287 million, above the guided range of $260 million to $270 million and a year-over-year growth rate of 24%. Revenue in Q1 was $511 million, higher than the guided range of $495 million to $505 million and a year-over-year growth rate of 18%. The outperformance was driven partly by stronger-than-expected performance from our U.S. federal government business, which grew significantly year-over-year in new ACV bookings. Our renewals performance also continued to be good. ARR at the end of Q1 was $1.664 billion, representing a year-over-year growth rate of 30%. Similar to last quarter, we saw a modest elongation of average sales cycles, relative to the year ago quarter. Average contract duration in Q1 was 2.9 years, slightly lower quarter-over-quarter and largely in line with our expectations, due to the higher mix of U.S. federal government business, which typically has lower contract duration. Non-GAAP gross margin in Q1 was 85.9%, higher than our expectations, due to higher revenue and a mix of factors leading to lower-than-expected cost of goods sold. Non-GAAP operating expenses were $360 million in Q1. Non-GAAP operating margin in Q1 was 15.6%, higher than our guided range of 9% to 11%, partly due to higher-than-expected revenue. Non-GAAP net income in Q1 was $85 million or EPS of $0.29 per share, based on fully diluted weighted average shares outstanding of approximately 293 million shares. Linearity was good, and DSOs, based on revenue and ending AR were 24 days in Q1. Free cash flow in Q1 was $132 million, implying free cash flow margin of 26%, higher than our expectations, largely due to better-than-expected bookings familiarity. We saw a larger-than-expected proportion of Q1 bookings in the first two months of the quarter. And since our payment terms are typically 30 to 45 days, more of the bookings were billed and collected in Q1, than expected. We ended Q1 with cash, cash equivalents and short-term investments of $1.571 billion, up from $1.437 billion in '23. Under the share repurchase program, authorized by our Board of Directors at the end of August, we began repurchasing shares in Q1, through a 10b5-1 plan. Given the timing of the authorization, we were in the market repurchasing shares for only a portion of Q1. Moving on to Q2. Our guidance for Q2 '24 is as follows: ACV billings of $295 million to $305 million; revenue of $545 million to $555 million; non-GAAP gross margin of 85% to 86%; non-GAAP operating margin of 14% to 16%; fully diluted shares outstanding of approximately 297 million shares. The updated guidance for full year fiscal year 2024 is as follows: ACV billings of $1.08 billion to $1.1 billion, representing year-over-year growth of 14% at the midpoint of the range; revenue of $2.095 billion to $2.125 billion, representing year-over-year growth of 13% at the midpoint; non-GAAP gross margin of approximately 85%; non-GAAP operating margin of 11.5% to 12.5%; free cash flow of $340 million to $360 million, representing free cash flow margin of 16.6% at the midpoint of the range. This updated fiscal year '24 guidance is higher than our previously provided fiscal year '24 guidance, across all metrics. I will now provide some additional commentary regarding our fiscal year '24 guidance. First, we are seeing continued new and expansion opportunities for our solutions, despite the uncertain macro environment. However, as we mentioned previously, we have continued to see a modest elongation of average sales cycles. Our fiscal year '24 new and expansion ACV performance outlook assumes some impact from these macro dynamics. Second, the guidance assumes that our renewals business will continue to perform well. And a reminder that while our available to renew, or ATR pool, continues to grow year-over-year, it is growing at a slower pace in fiscal year '24, but is expected to reaccelerate in fiscal year '25, based on our current view. Third, the full year guidance assumes that average contract duration would be flat to slightly lower, compared to fiscal year '23, as renewals continue to grow as a percentage of our billings. A reminder that the full year ACV billing is not the sum of the ACV billings of the four quarters, due to contracts with durations less than one year. We expect full year ACV billings to be about 5% to 6% lower than the sum of the four quarters ACV billings. Finally, a few thoughts on seasonality for the remainder of the fiscal year. Based on our current view, we expect the trend in top line metrics in Q3 relative to Q2, to be more or less similar to what we saw in fiscal year '23. A reminder that operating expenses tend to be slightly higher in Q3 versus Q2, all else being equal, as Q3 includes the full impact of calendar year resets to payroll taxes. In closing, we are pleased with our Q1 results exceeding guidance and to raise our top line and bottom line guidance for the full fiscal year. With that, operator, please open the line for questions.